Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy by Persson, Frederik et al.
Impact of Baseline Renal Function on the
Efﬁcacy and Safety of Aliskiren Added to
Losartan in Patients With Type 2 Diabetes
and Nephropathy
FREDERIK PERSSON, MD
1
JULIA B. LEWIS, MD
2
EDMUND J. LEWIS, MD
3
PETER ROSSING, DMSC
1
NORMAN K. HOLLENBERG, PHD
4
HANS-HENRIK PARVING, DMSC
5
FOR THE AVOID STUDY INVESTIGATORS*
OBJECTIVE — Proteinuric diabetic patients with reduced glomerular ﬁltration rate (GFR)
are at high risk of renal and cardiovascular disease progression and treatment-related adverse
events. This post hoc analysis assessed the efﬁcacy and safety of aliskiren added to the maximal
recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1–3 chronic
kidney disease [CKD]).
RESEARCH DESIGN AND METHODS — In the Aliskiren in the Evaluation of Protein-
uriainDiabetes(AVOID)study,599hypertensivepatientswithtype2diabetesandnephropathy
received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo
added to 100 mg losartan and optimal antihypertensive therapy. Exclusion criteria included
eGFR 30 ml/min per 1.73 m
2 and serum potassium 5.1 mmol/l.
RESULTS — BaselinecharacteristicsweresimilarbetweentreatmentgroupsinallCKDstages.
The antiproteinuric effects of aliskiren were consistent across CKD stages (19, 22, and 18%
reduction). In the stage 3 CKD group, baseline serum creatinine levels were equal, but renal
dysfunction, prespeciﬁed as a postrandomization serum creatinine elevation 176.8 mol/l
(2.0 mg/dl) occurred more frequently in the placebo group (29.2 vs. 13.6%, P  0.032). Serum
potassium elevations 5.5 mmol/l (based on a single measurement) were more frequent with
aliskiren (22.5 vs. 13.6%) in stage 3 CKD. Adverse event rates were similar between treatments,
irrespective of CKD stage.
CONCLUSIONS — Aliskiren added to losartan reduced albuminuria and renal dysfunction
and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in
patients with type 2 diabetes, hypertension, and nephropathy.
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R
enin inhibition is a new treatment
modality that blocks the renin-
angiotensin-aldosterone system
(RAAS)attheﬁrstrate-limitingstepofthe
cascade. Because the direct renin inhibi-
toraliskirenrecentlywasapprovedforthe
treatment of hypertension, it seemed a
reasonable assumption that this drug
would also possess antiproteinuric quali-
ties. In theory, renin inhibition will de-
crease plasma renin activity and levels of
circulating angiotensin I and angiotensin
II, leading to more efﬁcient RAAS block-
ade. A previous study from our group has
suggested a higher degree of RAAS block-
ade by the use of the combination of
aliskiren and the angiotensin II receptor
blocker irbesartan (1). Whereas this hy-
pothesis was formerly proven only in
small studies (1,2), the Aliskiren in the
Evaluation of Proteinuria in Diabetes
(AVOID) study (3) was the ﬁrst double-
blind, randomized controlled trial to
demonstrate the antiproteinuric ability of
aliskiren (300 mg once daily) as an
add-on to standard treatment, including
the recommended dose of an angiotensin
II receptor blocker (losartan), in patients
with type 2 diabetes, hypertension, and
nephropathy.
There is an evident unmet need for
improved renoprotective therapies be-
cause this patient group constitutes the
majority of patients requiring dialysis in
the western world (4). Reduction in pro-
teinuria from RAAS blockade has been
shown to be associated with improved re-
nal and cardiovascular prognosis (5,6),
and although its use remains controver-
sial, albuminuria is the best available sur-
rogate marker for renal protection.
Combinationtreatmentwithrenininhibi-
tion and angiotensin II receptor blockade
is evolving as a new antiproteinuric treat-
ment, but not much is known about the
impact of underlying renal function on
the safety and efﬁcacy of this treatment.
The aim of this post hoc analysis was to
investigate the efﬁcacy and safety of
add-on treatment with aliskiren in the
AVOIDstudyacrossdifferentstagesofes-
timated glomerular ﬁltration rate (eGFR)
at baseline.
RESEARCH DESIGN AND
METHODS— The trial enrolled hy-
pertensive patients, ranging in age from
18 to 85 years, with type 2 diabetes and
nephropathy (early morning urinary al-
bumin-to-creatinine ratio [UACR]) 300
mg/g or 200 mg/g in patients receiving
blockade of the RAAS). The criteria for
exclusion were known nondiabetic kid-
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30ml/minper1.73m
2(7),chronicuri-
nary tract infection, serum potassium
5.1 mmol/l at time of randomization,
severe hypertension, or major cardiovas-
cular disease within the last 6 months.
In a randomized, double-blind, pla-
cebo-controlled study conducted in 15
countries and 150 centers worldwide, we
evaluated the possible renoprotective ef-
fect of aliskiren in 599 hypertensive pa-
tients with type 2 diabetes and
nephropathy.Themethodshavebeende-
scribed in detail in the main publication
(3). In brief, we screened 1,892 eligible
patients at an enrollment visit. Subse-
quently 805 patients entered a 3-month
open-label period during which all previ-
ous drugs that block the RAAS were dis-
continued, except for -blockers, and
treatment was initiated with the maximal
recommended renoprotective dose of lo-
sartan (100 mg daily) plus additional an-
tihypertensive therapy aiming for an
optimal target blood pressure, i.e.,
130/80 mmHg. During the 3-month
open-labeltreatmentperiod,206patients
were excluded, leaving 599 randomly as-
signed patients who were followed for a
median of 6 months. Patients were ran-
domly assigned to receive aliskiren at a
dose of 150 mg once daily for 3 months,
followed by aliskiren at 300 mg daily for
another 3-month period or matching pla-
cebo once daily. The study protocol was
in accordance with the Declaration of
Helsinki (2002) and was approved by lo-
cal and central review boards. All patients
provided written informed consent.
The patients were examined 13, 12,
8, 4, and 2 weeks before randomization,
at randomization, and 1, 4, 8, 11, 12, 16,
and 24 weeks after randomization. Blood
pressure and pulse, adverse events, con-
comitant medications, and adherence to
medications were assessed at each visit.
Three early morning spot urine samples
were collected on three sequential days at
13and2weeksbeforerandomizationand
at 4, 8, 12, 16, and 24 weeks after ran-
domization.Threeovernighturinecollec-
tions were performed on three sequential
nights 2 weeks before randomization
(baseline) and 12 and 24 weeks after ran-
domization. The urinary albumin con-
centration was determined by
immunoturbidimetry (8) and the serum
creatinine concentration by Jaffe reaction
(Roche kit) (9). The Modiﬁcation of Diet
in Renal Disease (MDRD) formula was
used to estimate the glomerular ﬁltration
rate(GFR)(7).A1CwasmeasuredbyBio-
Rad high-performance liquid chromatog-
raphy (10). All of the remaining
laboratory variables were also measured
centrally by applying conventional labo-
ratory techniques.
Seated blood pressure was assessed
by standard mercury sphygmomanome-
ters with an appropriate cuff size after at
least 5 min of rest. Three measurements
were obtained, 2 min apart at each time
point, and the average of the three was
used for calculation of the 24-h trough
level (24 h postdose). The target blood
pressure during the open-label and dou-
ble-blind period was less than 130/80
mmHg for both groups. Consequently,
further adjustments in blood pressure–
lowering medication were recommended
after randomization. All classes of blood
pressure–lowering drugs were allowed,
except for drugs blocking the RAAS.
In this post hoc analysis, we com-
pared the effect of aliskiren versus pla-
cebo across the patients according to
baseline stage 1–3 of chronic kidney dis-
ease (CKD). In these albuminuric type 2
diabetic patients, the stage 1 group is de-
ﬁned as having eGFR 90 ml/min per
1.73 m
2, the stage 2 CKD group contains
patients with eGFR 60–90 ml/min
per1.73m
2,andthestage3CKDgroupis
deﬁned as having eGFR 60 ml/min per
1.73 m
2.
Theprimaryendpointcomparingthe
efﬁcacy of aliskiren treatment versus pla-
cebo was the reduction in UACR, based
Table 1—Baseline characteristics of the randomized population according to stage 1–3 CKD
Aliskiren Placebo P value
eGFR 60 ml/min per 1.73 m
2 129 119
Age (years) 63.1  8.2 65.4  8.5 0.030
Male sex (%) 83  64.3 84  70.6 0.295
Systolic blood pressure (mmHg) 136  12 135  12 0.550
Diastolic blood pressure (mmHg) 77  97 5  9 0.165
UACR (mg/g) 628 (89–3,175) 670 (103–3,393) 0.788
Serum creatinine (mol/l) 141.1  37.1 146.7  33.3 0.213
eGFR (ml/min per 1.73 m
2) 47.1 (22.8–59.9) 44.7 (24.6–59.7) 0.116
Serum potassium (mmol/l) 4.6  0.54 4.5  0.51 0.436
A1C (%) 8.2  1.5 7.7  1.4 0.004
Medical history (combined
cardiovascular disease, %) 32  24.8 26  21.8 0.583
eGFR 60– 90 ml/min per 1.73 m
2 104 122
Age (years) 59.8  8.3 60.7  9.2 0.450
Male sex (%) 74  71.2 96  78.7 0.191
Systolic blood pressure (mmHg) 134  11 133  10 0.966
Diastolic blood pressure (mmHg) 78  87 8  8 0.748
UACR (mg/g) 410 (105–2,984) 484 (110–3,097) 0.167
Serum creatinine (mol/l) 91.5  13.6 94.3  13.9 0.126
eGFR (ml/min per 1.73 m
2) 73.6 (60.8–89.9) 72.4 (60.0–89.7) 0.605
Serum potassium (mmol/l) 4.5  0.49 4.5  0.48 0.297
A1C (%) 7.8  1.3 8.0  1.4 0.320
Medical history (combined
cardiovascular disease, %) 20  19.2 24  19.7 0.933
eGFR 90 ml/min per 1.73 m
2 64 51
Age (years) 53.0  10.7 55.3  9.5 0.232
Male sex (%) 47  73.4 35  68.6 0.571
Systolic blood pressure (mmHg) 135  12 133  13 0.387
Diastolic blood pressure (mmHg) 80  87 8  10 0.422
UACR (mg/g) 530 (103–2,770) 405 (101–3,103) 0.929
Serum creatinine (mol/l) 69.3  10.6 68.2  10.1 0.570
eGFR (ml/min per 1.73 m
2) 102.5 (90.4–171.2) 100.4 (90.7–155.8) 0.776
Serum potassium (mmol/l) 4.4  0.46 4.4  0.38 0.906
A1C (%) 8.0  1.5 8.1  1.6 0.865
Medical history (combined
cardiovascular disease, %) 8  12.5 7  13.7 0.846
Data are n, mean  SD, or median (range). Patients with missing values were not included in the baseline
comparison.
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randomization to week 24, compared
acrosstheeGFRsubgroups.Secondaryef-
ﬁcacyendpointswerebetween-treatment
comparisons of urinary albumin excre-
tion rate reduction, based on overnight
samples, change in eGFR from baseline,
and comparison of the proportion of pa-
tients with 50% reduction in UACR
from randomization to week 24.
For evaluation of safety across eGFR
subgroups, we compared occurrences of
hyperkalemia (single measures of serum
potassium 5.5 and 6.0 mmol/l) and
investigator-reported incidences of hypo-
tension. In addition, development of re-
nal dysfunction (prespeciﬁed as serum
creatinine 176.8 mol/l [2.0 mg/dl])
was investigated.
Statistics
The following subgroups were deﬁned
based on baseline renal function: moder-
ate to severe renal dysfunction, eGFR
60 ml/min per 1.73 m
2 (stage 3 CKD),
mild renal dysfunction, eGFR 60–90
ml/min per 1.73 m
2 (stage 2 CKD), and
no renal dysfunction, eGFR 90 ml/min
per 1.73 m
2 (stage 1 CKD).
Log-transformed eGFR at week 24
was analyzed using ANCOVA. Subgroup,
treatment, subgroup by treatment inter-
action, region, and baseline proteinuria
classiﬁcation were ﬁtted as factors. Log-
transformed baseline eGFR was ﬁtted as a
covariate.
For between-treatment comparison
of rate of change in eGFR (milliliters per
minute per 1.73 m
2) by eGFR subgroup
with adjustment for covariates, an
ANCOVA model was ﬁtted to the rate of
change in eGFR, with baseline UACR,
baseline systolic blood pressure, baseline
A1C, baseline total cholesterol, and base-
line hemoglobin as covariates, with treat-
ment, region, age, sex, and eGFR
subgroup as factors and eGFR subgroup
by treatment as an interaction term.
For analyses of associations, a linear
regression model was ﬁtted to change
from baseline in eGFR with change from
baseline in log-transformed UACR as an
explanatory variable, treatment as a fac-
tor, and treatment by change from base-
line in log-transformed UACR as an
interaction term. The change from base-
line in eGFR was also analyzed using lin-
ear regression with change from baseline
in systolic blood pressure in the model
and treatment by change from baseline in
systolic blood pressure as the interaction
term.
RESULTS— Patient characteristics in
the three eGFR groups at baseline can be
seeninTable1.Thetwotreatmentgroups
were similar in all eGFR subgroups, ex-
ceptforadifferenceinageandinbaseline
A1C in the CKD stage 3 group. However,
this imbalance did not have an impact in
the subsequent statistical analysis. We
foundaconsistentUACRreductioninthe
aliskiren treatment groups, with a 19%
(95% CI 34–0) reduction in the stage 3
CKD group (P  0.045), a 22% (34–4)
reduction in the stage 2 CKD group (P 
0.021), and an 18% (39 to 11) reduc-
tion compared with placebo (P  0.202)
in the stage 1 CKD group (Fig. 1).
Figure 1—Difference in UACR after 24 weeks compared with baseline after treatment with
aliskiren or placebo as add-on to standard treatment including an optimal dose of the angiotensin
II receptor blocker losartan in type 2 diabetic patients with albuminuria. Groups according to
baseline CKD stage.
Table 2—End points
Aliskiren Placebo P value
eGFR 60 ml/min per 1.73 m
2 128 118
UACR change at 24 weeks (%) 9( 21 to 6) 13 (3 to 31) 0.045
UACR reduction 50 (%) 25/122 (20.2) 11/115 (9.6) 0.019
Change in eGFR (ml/min per
1.73 m
2) per 6 months 1.7 (6.2 to 2.9) 0.25 (4.5 to 5.0) 0.552
Serum creatinine elevation
176.8 mol/l* 15/110 (13.6) 28/96 (29.2) 0.032
Blood pressure change
SBP/DBP (mmHg) 2.4 (1.3)/1.0 (0.7) 4.7 (1.3)/0.6 (0.8) 0.166/0.094
eGFR 60–90 ml/min per
1.73 m
2 104 122
UACR change at 24 weeks (%) 23 (34 to 10) 1( 14 to 15) 0.021
UACR reduction 50 (%) 28/101 (27.7) 17/118 (14.4) 0.012
Change in eGFR (ml/min per
1.73 m
2) per 6 months 2.7 (7.6 to 2.3) 4.8 (9.3 to 0.2) 0.536
Serum creatinine elevation
176.8 mol/l* 1 (1.0) 3 (2.5) 0.627
Blood pressure change
SBP/DBP (mmHg) 0.7 (1.4)/0.3 (0.8) 1.8 (1.3)/0.5 (0.8) 0.547/0.843
eGFR90 ml/min per 1.73 m
2 63 51
UACR change at 24 weeks (%) 27 (40 to 10) 11 (29 to 12) 0.202
UACR reduction 50 (%) 18/62 (29.0) 8/50 (16.0) 0.132
Change in eGFR (ml/min per
1.73 m
2) per 6 months 5.6 (11.8 to 0.66) 9.5 (16.5 to 2.5) 0.410
Serum creatinine elevation
176.8 mol/l* 0 0 NA
Blood pressure change
SBP/DBP (mmHg) 1.4 (1.8)/0.6 (1.0) 0.9 (1.9)/1.2 (1.1) 0.352/0.218
Data are n, mean (SD), or median (range). Patients with missing values were not included in the analysis.
DBP, diastolic blood pressure; NA, not applicable; SBP, systolic blood pressure. *Development of serum
creatinine 176.8 mol/l after randomization.
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50% reduction in UACR were consis-
tently higher in the aliskiren-treated pa-
tients, reaching 29.0, 27.7, and 20.5% in
stages 1, 2, and 3, respectively, compared
with 16.0, 14.4, and 9.6% in the corre-
sponding placebo groups (between-
treatment differences P  0.132, P 
0.012, and P  0.019, respectively)
(Table 2).
The changes in eGFR over the
6-month duration of the study can be
seen in Table 2. Notably, there were no
statistically signiﬁcant differences be-
tweentreatmentsinchangesineGFR,but
inthestage1groupthechangeineGFRin
the aliskiren group was 5.6 (11.8 to
0.66) ml/min per 6 months, numerically
lower than that in the placebo group,
changing 9.5 (16.5 to 2.5) ml/min
per 6 months. Adjustment of the changes
in eGFR for clinical covariates in the
ANCOVA model did not signiﬁcantly al-
tertheresults.Overall,areductioninsys-
tolic blood pressure was associated with a
changeineGFRinbothtreatmentgroups,
and (although not signiﬁcant) the ten-
dency remained in the eGFR subgroups,
except in the placebo group in the eGFR
90 ml/min per 1.73 m
2 subgroup (data
not shown).
Adverse event rates were highest in
thestage3CKDgroup(68.1–72.9%)and
lowest in the stage 1 CKD group (59.4–
60.8%);therewerenonotabledifferences
between treatments in any subgroup (Ta-
ble 3). In the stage 3 CKD group, hyper-
kalemia, based on a single measurement
of serum potassium 5.5 mmol/l, was
more frequent in the aliskiren-treated pa-
tients (22.5%) compared with that in the
placebo group (13.6%), although this
value was not statistically signiﬁcant (P 
0.07). There were no differences between
the other treatment groups (Table 3). Se-
vere hyperkalemia (serum potassium
6.0 mmol/l) in the stage 3 group was
registered in 11 aliskiren-treated patients
(8.5%) compared with 4 placebo-treated
patients (3.4%) (P  0.113). However, 9
of the 11 aliskiren-treated patients dis-
played serum potassium levels 5.1
mmol/l at baseline and should have been
excluded from randomization according
to the study protocol. Four of these pa-
tients left the study shortly after
randomization.
Symptoms of hypotension (investiga-
tor deﬁned) were not a frequent adverse
event, with no differences between treat-
ments in any eGFR subgroup (Table 3).
In the stage 3 CKD group there was a
signiﬁcant difference in development of
renal dysfunction (prespeciﬁed as devel-
opment of serum creatinine 176.8
mol/l after randomization) during the
course of the study (excluding patients
who already had serum creatinine
176.8 mol/l at the time of randomiza-
tion). In the placebo-treated group,
29.2% developed renal dysfunction com-
pared with 13.6% in the aliskiren group
(P  0.032) (Table 3).
CONCLUSIONS— In this post hoc
analysisoftheresultsoftheAVOIDstudy,
we demonstrate that the reduction in
UACR from add-on aliskiren treatment
was independent of baseline renal func-
tion, and, thus, aliskiren can be of added
beneﬁt to standard treatment (including
theoptimaldoseoftheangiotensinrecep-
torblockerlosartan)inpatientswithstage
1–3 CKD. In addition, the proportion of
aliskiren-treatedpatientsachievinga50%
reductioninUACRwassimilarinallthree
stages, approximately twice the propor-
tion of placebo-treated patients. There
were no signiﬁcant differences in systolic
or diastolic blood pressure change from
baseline in any eGFR subgroup, but over-
all the reduction in systolic blood pres-
sure was associated with a reduction in
eGFR in both aliskiren- and placebo-
treated groups.
From a safety point of view, we
found that hyperkalemia, based on a
single measurement of serum potas-
sium, was more common in aliskiren-
treated patients with stage 3 CKD. This
result represents a side effect to this
therapy that must be considered, given
the above-noted beneﬁt. It is possible
that more frequent serum potassium
control and concomitant use of loop di-
uretics in these patients would amelio-
ratethis.Wewerenotabletoinvestigate
in detail the inﬂuence of other concom-
itant medications on the levels of potas-
sium, but the use of potassium-sparing
diuretics and ACE inhibitors was not
allowed in the study. Severe hyperkale-
mia, deﬁned as a single serum potas-
siumresult6.0mmol/l,wasalsomore
common in stage 3 CKD; however, 9 of
the11aliskiren-treatedpatientsinstage
3 CKD with severe hyperkalemia were
randomly assigned despite violating the
exclusion limit of serum potassium
5.1 mmol/l stated in the study
protocol.
Importantly, however, we also found
thataliskiren-treatedpatientswithstage3
CKD had a lower incidence of develop-
ment of renal dysfunction, underlining
the improved renal prognosis in these pa-
tients, provided that other safety mea-
sures are taken into consideration. Of
note,intheoverallstudypopulationthere
was a low incidence of death or acute re-
Table 3—Adverse events according to stage 1–3 CKD
Aliskiren Placebo P value
eGFR 60 ml/min per 1.73 m
2 129 119
Serum potassium 6.0 mmol/l 11  8.5 4  3.4 0.113
Serum potassium 5.5 mmol/l 29  22.5 16  13.6 0.070
Any adverse event 94  72.9 81  68.1 0.407
Any serious adverse event 12  9.3 11  9.2 0.987
Discontinuations due to an adverse event 10  7.8 7  5.9 0.561
Hypotension 5  3.9 1  0.8 0.215
eGFR 60–90 ml/min per 1.73 m
2 104 122
Serum potassium 6.0 mmol/l 3  2.9 1  0.8 0.336
Serum potassium 5.5 mmol/l 10  9.6 14  11.5 0.651
Any adverse event 67  64.4 83  68.0 0.567
Any serious adverse event 13  12.5 10  8.2 0.286
Discontinuations due to an adverse event 7  6.7 7  5.7 0.758
Hypotension 5  4.8 1  0.8 0.097
eGFR 90 ml/min per 1.73 m
2 64 51
Serum potassium 6.0 mmol/l 0 0 NA
Serum potassium 5.5 mmol/l 2  3.2 2  3.9 1.000
Any adverse event 38  59.4 31  60.8 0.878
Any serious adverse event 2  3.1 6  11.8 0.136
Discontinuations due to an adverse event 0 5  9.8 0.015
Hypotension 2  3.1 0 0.502
DataarenormeanSD.Patientswithmissingvalueswerenotincludedintheanalysis.NA,notapplicable.
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between the groups (0.7% in both
groups).
Despite the differences in overall
rates of renal dysfunction (new devel-
opment of serum creatinine 176.8
mol/l/2.0 mg/dl), eGFR in the two
treatment groups in patients with stage
3 CKD did not differ signiﬁcantly.
When GFR is small, with a substantial
portion of patients having no detectable
eGFR decline, a time-to-event analysis
has greater statistical power to detect a
treatment effect than a slope-based ef-
fect (11). The Ramipril in Non-Diabetic
RenalFailure(REIN)andMDRDstudies
support the validity of this analysis in
nondiabetic nephropathies (12,13).
The efﬁcacy and safety of aliskiren
treatmenthasbeenassessedinafewstud-
ies. In a short-term double-blind cross-
over study (1), we investigated aliskiren
treatment compared with and in combi-
nation with irbesartan in patients with
type 2 diabetes and albuminuria, with
baselinelevelsofGFRaslowas40ml/min
per1.73m
2.Wefoundnosignofreduced
efﬁcacy or safety of the drug in patients
with impaired renal function. In a phar-
macokinetic study of 17 men with mild,
moderate, or severe renal impairment
(creatinineclearance50–80,30–49,and
30 ml/min, respectively) and matched
controlsubjects,aliskirenwasfoundtobe
well tolerated when administered alone
or with irbesartan (14).
A study of healthy people consuming
a low-sodium diet has shown that renal
vasodilation with aliskiren far exceeds
that seen with ACE inhibitors and angio-
tensin II receptor blockers (15). The in-
crease in renal plasma ﬂow may be a
response to AT1 receptor-dependent re-
ductionofthevasculartoneintheefferent
arteriole. These results indicate that
aliskiren may provide greater and thus
more effective blockade of the renin sys-
tem in the kidney. Because the activity of
the renin-angiotensin system is enhanced
in patients with diabetes, compared with
that in control subjects (16), a more pro-
nounced difference in renal vasodilata-
tion may be expected during aliskiren
therapy. Studies in patients with uncom-
plicatedtype1diabetesconsuminganor-
mal salt diet have demonstrated that
aliskiren enhances renal plasma ﬂow and
GFR, independent of glycemic control
(17). Both studies (15,17) found a reduc-
tion in ﬁltration fraction and a GFR
dependency of renal plasma ﬂow, sup-
porting the presence of a ﬁltration pres-
sure equilibrium in humans (i.e.,
ﬁltration stops along the glomerular cap-
illaries as oncotic pressure equals hydro-
static pressure). It is suggested that with
an increase in renal plasma ﬂow there is a
shift to the right of this equilibrium, lead-
ing to a greater surface area available for
ﬁltration, as ﬁltration stops at a later
point. The concomitant decrease in intra-
glomerular pressure will lead to a reduc-
tion in albuminuria.
The change in eGFR from baseline to
6 months was more pronounced in pa-
tients with well-preserved kidney func-
tion (stage 1 and 2 CKD) compared with
reducedeGFR(stage3CKD).Hyperﬁltra-
tion and regression to the mean may con-
tribute to these ﬁndings. Observational
studies (18) and treatment trials applying
completely different interventions have
resulted in similar ﬁndings in proteinuric
type 2 diabetic patients (D. de Zeeuw,
personal communication).
When the results of our analysis are
interpreted, the post hoc nature of the
analysismustbetakenintoconsideration.
Statistical comparisons were made with-
out adjustment for multiple testing, but
all analyses were prespeciﬁed and results
were consistent between groups. It must
berememberedthatthereportedchanges
in eGFR were recorded over only 6
months. Optimally, studies of at least 2
years duration are needed to properly as-
sess changes in eGFR in relation to out-
come. This will be possible, along with
assessmentoftheeffectofrenininhibition
oncardiorenalhardendpoints,intheon-
going Aliskiren Trial in Type 2 Diabetes
Using Cardio-Renal Endpoints (ALTI-
TUDE) study (19). In addition, we were
notabletoassesstheeffectoftreatmentin
patients with stage 4 and 5 CKD, as such
patients were not included in the AVOID
study owing to safety concerns.
In summary, aliskiren as add-on
treatment to standard therapy including
the optimal dose of the angiotensin II re-
ceptor blocker losartan, in the AVOID
study, reduced albuminuria and slowed
development of renal dysfunction more
than placebo across different levels of
eGFRinpatientswithtype2diabetes,hy-
pertension,andnephropathy.Hyperkale-
mia is more frequent in the aliskiren-
treated patients with stage 3 CKD.
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